11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
Catalyst Pharmaceuticals Inc. (CPRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 3,133,011 | $65,385,940 | -50% | 1.23% |
| 2. | Renaissance Technologies Jim Simons | 2,706,116 | $56,476,641 | +8% | 0.08% |
| 3. | Royce & Associates Chuck Royce | 1,864,351 | $38,909,005 | -8% | 0.36% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 698,152 | $14,570,432 | +132% | 0.01% |
| 5. | Millennium Management Israel Englander | 520,778 | $10,868,637 | -7% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.99 | 7,000 | Director | 560,376 | 2020-09-30 | Filing | |
| $2.97 | 15,000 | Officer, Director | 4,787,693 | 2020-09-30 | Filing | |
| $4.70 | 10,000 | Director | 553,376 | 2019-10-11 | Filing | |
| $4.89 | 10,000 | Officer, Director | 4,772,693 | 2019-10-03 | Filing | |
| $3.23 | 25,000 | Officer, Director | 4,762,693 | 2019-06-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.67 | 180,096 | Officer | 68,873 | 2025-03-06 | Filing | |
| $22.09 | 44,904 | Officer | 68,873 | 2025-03-05 | Filing | |
| $22.93 | 53,255 | Officer | 188,564 | 2025-03-03 | Filing | |
| $23.23 | 9,720 | Officer | 188,564 | 2025-03-03 | Filing | |
| $22.89 | 30,423 | Officer | 0 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,425,129 | $405,402,449 | 0% | |
| 2. | 8,431,094 | $175,956,931 | 0% | |
| 3. | 5,796,560 | $120,974,207 | 0% | |
| 4. | 3,013,032 | $62,884,059 | 0.01% | |
| 5. | 2,955,508 | $61,681,452 | 0.13% |
News See All
Jim Cramer Discussed These 6 Stocks Recently
On Tuesday, Jim Cramer, host of Mad Money, defended the growing wave of artificial intelligence investment, drawing a distinct line between this boom and previous capital expenditure surges.
10 Best Healthcare Stocks For Long-Term Investment
In the US, healthcare expenditures and costs have been increasing. According to the Centers for Medicare & Medicaid Services, US healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Catalyst Pharmaceuticals Fourth Quarter and Full-Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Kris and I will be your conference operator today.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Catalyst Pharmaceuticals' Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Catalyst Pharmaceuticals' First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024
In this article, we will take a detailed look at Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024. For a quick overview of such stocks, read our article Jim Cramer’s 5 Favorite Healthcare...
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2023 Earnings Call Transcript
Operator: Hello, and welcome to the Catalyst Pharmaceuticals Inc. Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast.